Quince Therapeutics, Inc.
corporate_fare Company Profile
Quince Therapeutics, Inc. (NASDAQ:QNCX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 36 items for QNCX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-09, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for QNCX spans 8-K, DEF 14A, 10-Q, PRE 14A.
Recent high-impact activity:
- Quince Therapeutics Names Brigette Roberts CEO Amid Restructuring
- Quince Therapeutics Rebrands as IRulya Therapeutics with New Leadership and $116M Cash Runway Through 2028
- Quince Stockholders Approve Series C Conversion, Authorized Share Increase, and New Equity Plans
- Quince Sells AIDE/eDSP Assets for $450K, Finalizes President's $1M Severance
- Nasdaq Delisting Notice Hits Quince Therapeutics on Negative Equity
Dilution Risk
Low riskFiling-implied dilution signals for QNCX, detected from its recent SEC filings.
S-3 Amendment Filed · Resale Registration Details
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →